Analysis of deaths in the cohort of patients who suffered COVID and neurological manifestations: the results of the energy study in the Republic of Moldova

Authors

  • Oxana GROSU Institute of Neurology and Neurosurgery "Diomid Gherman"
  • Galina ZOLOTCO "Nicolae Testemitanu" State University of Medicine and Pharmacy

DOI:

https://doi.org/10.52692/1857-0011.2022.3-74.14

Keywords:

COVID 19, mortality, ENERGY, neurological manifestations

Abstract

Several studies have evaluated risk factors associated with mortality related to COVID-19. Important risk factors associated with an increased mortality rate include older age, male sex, current smoking, baseline comorbidities (especially chronic renal, respiratory, and cardio-cerebrovascular disease), dyspnea symptoms, complications during hospitalization, corticosteroid therapy, and a severe condition.The aim of the research was to characterize and analyze the cohort of patients who died with neurological manifestations and COVID 19. Materials and methods: The analysis of the cohort of patients from the Republic of Moldova included in the ENERGY Registry was performed. The Republic of Moldova cohort at the time of publication included 200 patients, who were assessed by telephone every 6 months. 58 patients who died were identified and included in the study. Deaths occurred in both the initial and follow-up phases. Statistical data were extracted and analyzed using SPSS. Results and discussion: The mean age of the patients included in the study group was 70.6 ± 12.1 years. There were 37 women (63.8%) and 21 men (36.2%). The deceased subjects presented comorbidities in 91.4% (53p) cases, being as follows: hypertension (89.7%), coronary heart disease – 29.3% cases, DM type II – 27.6%, renal pathologies (17.2%), liver (6.9%), anemia (6.9%), lung disease (3.4%), presence of cancer – 12.1% and immunosuppression (1.7%). Pre-existing neurological pathologies were present in 44.8% (26 p) of the examined patients, the most important being: stroke (27.6%), dementia (5.2%) and neuropathy (1.7%). 79.3% of patients were admitted to the Intensive Care Unit. Correlation analysis demonstrated a positive correlation between patient death and the presence of diabetes (r=0.163, p=0.034), the presence of any complications (r=0.163, p=0.034), pneumonia (r=0.201, p=0.07) and the need for ventilation support (r=0.206, p=0.007). Conclusions: The cohort of patients who died with COVID 19 and neurological manifestations from the Republic of Moldova has a remarkably high mortality rate (34.3%): patients with comorbidities, pre-existing neurological pathologies, who presented pulmonary complications that required ventilatory support and treatment in intensive care.

Author Biographies

Oxana GROSU, Institute of Neurology and Neurosurgery "Diomid Gherman"

dr. șt. med.,cercet. șt.

Galina ZOLOTCO, "Nicolae Testemitanu" State University of Medicine and Pharmacy

medic rezident, cercet. șt. stagiar

References

Chou SHY, Beghi E, Helbok R, Moro E, Sampson J, Altamirano V, et al. Global Incidence of Neurological Manifestations among Patients Hospitalized with COVID-19 A Report for the GCS-NeuroCOVID Consortium and the ENERGY Consortium. JAMA Netw Open. 2021;

Elrobaa IH, New KJ. COVID-19: Pulmonary and Extra Pulmonary Manifestations. Vol. 9, Frontiers in Public Health. 2021.

Beghi E, Helbok R, Crean M, Chou SHY, McNett M, Moro E, et al. The European Academy of Neurology COVID-19 registry (ENERGY): an international instrument for surveillance of neurological complications in patients with COVID-19. Eur J Neurol. 2021;28(10).

Popa V, Grosu O, Lisnic V, Gavriliuc M, Odainic O, Manvelov A, et al. Preliminary results of the ENERGY study ( Ean NEuro-covid ReGistrY ) in the Republic of Moldova. 2021;64(September):2021.

Grosu O, Popa V, Manvelov A, Cebotari E. Stroke as the main presentation in the moldovan cohort of patients with covid and neurological manifestation. Int J Stroke. 2021;16(2):849.

Beghi E, Helbok R, Ozturk S, Karadas O, Lisnic V, Grosu O, et al. Shortand long-term outcome and predictors in an international cohort of patients with neuro-COVID-19. Eur J Neurol. 2022;29(6).

Yassin A, Nawaiseh M, Shaban A, Alsherbini K, El-Salem K, Soudah O, et al. Neurological manifestations and complications of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. BMC Neurol. 2021;21(1).

Nepal G, Rehrig JH, Shrestha GS, Shing YK, Yadav JK, Ojha R, et al. Neurological manifestations of COVID-19: A systematic review. Crit Care. 2020;24(1).

Geng JS, Yu XL, Bao HN, Feng Z, Yuan XY, Zhang JY, et al. Chronic Diseases as a Predictor for Severity and Mortality of COVID-19: A Systematic Review With Cumulative Meta-Analysis. Vol. 8, Frontiers in Medicine. 2021.

Nath A, Smith B. Neurological complications of COVID-19: from bridesmaid to bride TT Complicações neurológicas do COVID-19: de dama de honra à noiva. Arq neuropsiquiatr. 2020;78(8).

Lu L, Zhong W, Bian Z, Li Z, Zhang K, Liang B, et al. A comparison of mortality-related risk factors of COVID-19, SARS, and MERS: A systematic review and meta-analysis. Vol. 81, Journal of Infection. 2020.

Chidambaram V, Tun NL, Haque WZ, Majella MG, Sivakumar RK, Kumar A, et al. Predictors of Severity and Mortality Among Patients with Coronavirus Disease 2019: A Systematic Review and Meta-Analysis. SSRN Electron J. 2020;

Al Saleh M, Alotaibi N, Schrapp K, Alsaber A, Pan J, Almutairi F, et al. Risk Factors for Mortality in Patients with COVID-19: The Kuwait Experience. Med Princ Pract. 2022;31(2).

Keyhanian K, Umeton RP, Mohit B, Davoudi V, Hajighasemi F, Ghasemi M. SARS-CoV-2 and nervous system: From pathogenesis to clinical manifestation. Vol. 350, Journal of Neuroimmunology. 2021.

Leven Y, Bösel J. Neurological manifestations of COVID-19 – an approach to categories of pathology. Neurol Res Pract. 2021;3(1).

Helbok R, Chou SHY, Beghi E, Mainali S, Frontera J, Robertson C, et al. NeuroCOVID: it’s time to join forces globally. Vol. 19, The Lancet Neurology. 2020.

Cebotari E, Grosu O, Odobescu S, Rotaru L, Corcea G, Moldovanu I. Medication overuse in patients with headache during the COVID-19 pandemic. 2021;64(September):80009.

Lai CC, Ko WC, Lee PI, Jean SS, Hsueh PR. Extra-respiratory manifestations of COVID-19. Int J Antimicrob Agents. 2020;56(2).

Harapan BN, Yoo HJ. Neurological symptoms, manifestations, and complications associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 19 (COVID-19). Vol. 268, Journal of Neurology. 2021.

Grosu O, Zolotco G, Corcea G. Subarachnoid hemorrhage associated with COVID-19 infection. Int J Stroke [Internet]. 2021;16(2 SUPPL):162. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L636514382&from=export%0Ahttp://dx. doi.org/10.1177/17474930211041949

Cazacu C, Caliga I, Moldovanu I, Odobescu S, Rotaru L, Corcea G, et al. Cerebral venous thrombosis after COVID-9 infection : case report. Mold Med J. 2021;64(September):2021.

Popa V, Grosu O, Manvelov A, Cebotari E. NEUROLOGICAL COMPLICATIONS IN PATIENTS WITH COVID-19 INFECTIONS: RESULTS OF ENERGY STUDY IN THE REPUBLIC OF MOLDOVA. 2021;(1):207.

Dewanjee S, Vallamkondu J, Kalra RS, Puvvada N, Kandimalla R, Reddy PH. Emerging COVID-19 Neurological Manifestations: Present Outlook and Potential Neurological Challenges in COVID-19 Pandemic. Vol. 58, Molecular Neurobiology. 2021.

Published

2022-12-12

Issue

Section

Research Article

Categories